Ivosidenib

艾伏尼布

Report date: 2026/05/17 20:00:15
NMEFirst In Class

Base Information

Drug NameIvosidenib
Drug Alias Nameivonibivonib tabletTuoshuwoTibsovo拓舒沃 +[13] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionIsocitrate dehydrogenase [NADP] cytoplasmic inhibitors
TargetsIsocitrate dehydrogenase [NADP] cytoplasmic
Therapy Area/IndicationsSolid tumoursMyeloproliferative DisordersMyelodysplastic Syndromes +[28] 
Global Approved IndicationsCholangiocarcinomaLeukemia, Myeloid, Acute
Approved Indications in ChinaLeukemia, Myeloid, Acute
Original Approved Country/TerritoryUnited States
Original Approved Date2018/07/20
Country/TerritoryCzechiaBelgiumArmenia +[30] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAgios Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesServier Affaires MédicalesServier Deutschland GmbhServier Bio-Innovation LLC +[18] 
Inactive CompaniesSharp CorpCstone Pharmaceuticals (Suzhou) Co Ltd
Active IndicationsSolid tumoursMyeloproliferative DisordersMyelodysplastic Syndromes +[26] 
Inactive IndicationsHepatic InsufficiencyNeoplasms

Other Information

ATC CodeL01XX62
Related LinksDrugBankKEGG